Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Editas Medicine Inc., 3 years.
Editas Medicine Inc.
Director
Scholar Rock Holding Corporation
Director · President of R&D
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 27, 2024 | Scholar Rock Holding Corporation | Grant or award | +13,500 | — | — |
| Aug 4, 2023 | Alnylam Pharmaceuticals Inc. | Open-market sale | −771 | $184.70 | $142,404 |
| Aug 4, 2023 | Alnylam Pharmaceuticals Inc. | Open-market sale | −1,869 | $185.54 | $346,774 |
| Aug 4, 2023 | Alnylam Pharmaceuticals Inc. | Open-market sale | −1,107 | $186.39 | $206,334 |
| Aug 4, 2023 | Alnylam Pharmaceuticals Inc. | Open-market sale | −101 | $187.37 | $18,924 |
| Aug 4, 2023 | Alnylam Pharmaceuticals Inc. | Open-market sale | −17 | $188.40 | $3,203 |
| Aug 4, 2023 | Alnylam Pharmaceuticals Inc. | Open-market sale | −192 | $189.31 | $36,348 |
| Aug 3, 2023 | Alnylam Pharmaceuticals Inc. | Grant or award | +5,082 | — | — |
| Aug 3, 2023 | Alnylam Pharmaceuticals Inc. | Grant or award | +3,859 | — | — |
| Apr 27, 2023 | Alnylam Pharmaceuticals Inc. | Open-market sale | −197 | $193.18 | $38,056 |
| Apr 27, 2023 | Alnylam Pharmaceuticals Inc. | Open-market sale | −910 | $193.93 | $176,476 |
| Apr 27, 2023 | Alnylam Pharmaceuticals Inc. | Open-market sale | −1,013 | $194.94 | $197,474 |
| Apr 27, 2023 | Alnylam Pharmaceuticals Inc. | Open-market sale | −104 | $195.65 | $20,348 |
| Apr 27, 2023 | Alnylam Pharmaceuticals Inc. | Open-market sale | −168 | $197.08 | $33,109 |
| Apr 26, 2023 | Alnylam Pharmaceuticals Inc. | Grant or award | +5,312 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.